Gianpietro Dotti

List of Publications by Year in Descending Order

199 papers	17,139 citations	68 h-index	130 g-index
202 ext. papers	20,657 ext. citations	8.9 avg, IF	6.42 L-index

#	Paper	IF	Citations
199	Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. **2022**, 10,		2
198	Scattered seeding of CAR T cells in solid tumors augments anticancer efficacy.. *National Science Review*, **2022**, 9, nwab172	10.8	9
197	Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells.. *Nature Biotechnology*, **2022**,	44.5	3
196	Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration.. *Nature Communications*, **2022**, 13, 2154	17.4	2
195	Inadvertent Transfer of Murine VL30 Retrotransposons to CAR-T Cells. *Advances in Cell and Gene Therapy*, **2022**, 2022, 1-21	1.2	
194	Fibrin gel enhances the antitumor effects of chimeric antigen receptor T cells in glioblastoma. *Science Advances*, **2021**, 7, eabg5841	14.3	9
193	Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells. *Cancer Cell*, **2021**,	24.3	5
192	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. *Journal of Experimental Medicine*, **2021**, 218,	16.6	21
191	Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells. *Molecular Cancer Therapeutics*, **2021**, 20, 577-588	6.1	5
190	Fully human antibody V domains to generate mono and bispecific CAR to target solid tumors **2021**, 9,		3
189	Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets. *Nature Biomedical Engineering*, **2021**, 5, 1038-1047	19	39
188	Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. *Nature Communications*, **2021**, 12, 2773	17.4	13
187	Modifications to the Framework Regions Eliminate Chimeric Antigen Receptor Tonic Signaling. *Cancer Immunology Research*, **2021**, 9, 441-453	12.5	7
186	Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity. *Blood*, **2021**, 137, 3306-3309	2.2	4
185	Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. *Clinical Cancer Research*, **2021**, 27, 3141-3153	12.9	12
184	Dual Targeting CAR-T Cells with Optimal Costimulation and Metabolic Fitness enhance Antitumor Activity and Prevent Escape in Solid Tumors. *Nature Cancer*, **2021**, 2, 904-918	15.4	6
183	Cryo-shocked cancer cells for targeted drug delivery and vaccination. *Science Advances*, **2020**, 6,	14.3	25

182	Scaffold-Mediated Static Transduction of T Cells for CAR-T Cell Therapy. *Advanced Healthcare Materials*, **2020**, 9, e2000275	10.1	7
181	Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 3687-3692	11.5	83
180	Enhancing Chimeric Antigen Receptor T-Cell Efficacy in Solid Tumors. *Clinical Cancer Research*, **2020** , 26, 2444-2451	12.9	50
179	Interleukin-23 engineering improves CAR T cell function in solid tumors. *Nature Biotechnology*, **2020**, 38, 448-459	44.5	74
178	In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab. *International Journal of Cancer*, **2020**, 146, 236-247	7.5	12
177	GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. *Nature Cancer*, **2020**, 1, 990-997	15.4	13
176	Activation and degranulation of CAR-T cells using engineered antigen-presenting cell surfaces. *PLoS ONE*, **2020**, 15, e0238819	3.7	1
175	Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. *Nature Medicine*, **2020**, 26, 1686-1690	50.5	73
174	THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells. *Cancer Cell*, **2020**, 37, 216-225.e6	24.3	44
173	Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2020**, 38, 3794-3804	2.2	90
172	Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. *Nature Communications*, **2020**, 11, 4810	17.4	39
171	The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. *Cell Communication and Signaling*, **2020**, 18, 134	7.5	13
170	CSPG4-Specific CAR.CIK Lymphocytes as a Novel Therapy for the Treatment of Multiple Soft-Tissue Sarcoma Histotypes. *Clinical Cancer Research*, **2020**, 26, 6321-6334	12.9	5
169	CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. *International Journal of Cancer*, **2020**, 146, 2531-2538	7.5	9
168	Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy. *Science Advances*, **2019**, 5, eaaw6870	14.3	131
167	B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres. *EBioMedicine*, **2019**, 47, 33-43	8.8	45
166	NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced Persistence and Antitumor Activity against Neuroblastoma. *Clinical Cancer Research*, **2019**, 25, 7126-7138	12.9	63
165	T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. *Clinical Cancer Research*, **2019**, 25, 7340-7350	12.9	18

164	Adipocytes as Anticancer Drug Delivery Depot. *Matter*, **2019**, 1, 1203-1214	12.7	32
163	Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. *Oncotarget*, **2019**, 10, 2369-2383	3.3	48
162	An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2019**, 39, e70-e78	7.1	19
161	Cancer Immunotherapy with T Cells Carrying Bispecific Receptors That Mimic Antibodies. *Cancer Immunology Research*, **2019**, 7, 773-783	12.5	13
160	Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth. *International Journal of Cancer*, **2019**, 145, 1935-1945	7.5	32
159	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. *Cancer Cell*, **2019**, 35, 221-237.e8	24.3	157
158	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). *Biology of Blood and Marrow Transplantation*, **2019**, 25, S63	4.7	13
157	Eradication of Neuroblastoma by T Cells Redirected with an Optimized GD2-Specific Chimeric Antigen Receptor and Interleukin-15. *Clinical Cancer Research*, **2019**, 25, 2915-2924	12.9	79
156	In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. *Nature Nanotechnology*, **2019**, 14, 89-97	28.7	424
155	In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. *Science Translational Medicine*, **2018**, 10,	17.5	318
154	Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells. *Molecular Therapy*, **2018**, 26, 963-975	11.7	61
153	Constitutive and TNF[illegible]nducible expression of chondroitin sulfate proteoglycan 4 in glioblastoma and neurospheres: Implications for CAR-T cell therapy. *Science Translational Medicine*, **2018**, 10,	17.5	67
152	PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy. *Advanced Materials*, **2018**, 30, e1707112	24	138
151	T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. *Clinical Cancer Research*, **2018**, 24, 2920-2934	12.9	38
150	Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in Transposon-Engineered T Cells. *Molecular Therapy - Methods and Clinical Development*, **2018**, 8, 131-140	6.4	33
149	Engineering PD-1-Presenting Platelets for Cancer Immunotherapy. *Nano Letters*, **2018**, 18, 5716-5725	11.5	113
148	A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia. *Clinical Cancer Research*, **2018**, 24, 6185-6194	12.9	106
147	CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30 and CD30 Embryonal Carcinoma via Antigen-Dependent and Fas/FasL Interactions. *Cancer Immunology Research*, **2018**, 6, 1274-1287	12.5	30

146	CD30-Chimeric Antigen Receptor (CAR) T Cells for Therapy of Hodgkin Lymphoma (HL). *Blood*, **2018** , 132, 680-680	2.2	16
145	Pre-Clinical Evaluation of B7-H3-Specific Chimeric Antigen Receptor T-Cells for the Treatment of Acute Myeloid Leukemia. *Blood*, **2018**, 132, 701-701	2.2	5
144	Clinical Responses to CAR.CD30-T Cells in Patients with CD30+ Lymphomas Relapsed after Multiple Treatments Including Brentuximab Vedotin. *Blood*, **2018**, 132, 681-681	2.2	10
143	Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma. *Journal of Clinical Oncology*, **2018**, 36, 1128-1139	2.2	98
142	Cancer Immunotherapy: PD-1 Blockade Cellular Vesicles for Cancer Immunotherapy (Adv. Mater. 22/2018). *Advanced Materials*, **2018**, 30, 1870152	24	13
141	In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. *Molecular Therapy*, **2018**, 26, 2727-2737	11.7	107
140	Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy. *Nature Biomedical Engineering*, **2018**, 2, 831-840	19	143
139	Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells. *Clinical Cancer Research*, **2017**, 23, 3499-3509	12.9	52
138	Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. *Molecular Therapy*, **2017**, 25, 580-592	11.7	136
137	HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial. *JAMA Oncology*, **2017**, 3, 1094-1101	13.4	378
136	Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. *Cancer Immunology Research*, **2017**, 5, 571-581	12.5	151
135	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. *Journal of Immunology*, **2017**, 199, 348-362	5.3	30
134	CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. *Molecular Therapy*, **2017**, 25, 2214-2224	11.7	249
133	A melanin-mediated cancer immunotherapy patch. *Science Immunology*, **2017**, 2,	28	209
132	Chimeric antigen receptor T-cells for B-cell malignancies. *Translational Research*, **2017**, 187, 59-82	11	17
131	Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity. *Human Gene Therapy*, **2017**, 28, 437-448	4.8	47
130	Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes. *Journal of Clinical Investigation*, **2017**, 127, 3462-3471	15.9	215
129	A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. *Cytotherapy*, **2016**, 18, 985-994	4.8	55

128	Chimeric antigen receptor-redirected T cells return to the bench. *Seminars in Immunology*, **2016**, 28, 3-9	10.7	22
127	Clonal Dynamics In Vivo of Virus Integration Sites of T Cells Expressing a Safety Switch. *Molecular Therapy*, **2016**, 24, 736-45	11.7	7
126	Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation. *Molecular Therapy*, **2016**, 24, 823-31	11.7	23
125	Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13R□-positive Glioma. *Molecular Therapy*, **2016**, 24, 354-363	11.7	62
124	CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo. *Journal of Clinical Investigation*, **2016**, 126, 2341-55	15.9	88
123	Selection bias: maintaining less-differentiated T cells for adoptive immunotherapy. *Journal of Clinical Investigation*, **2016**, 126, 35-7	15.9	5
122	Clinical responses with T lymphocytes targeting malignancy-associated □light chains. *Journal of Clinical Investigation*, **2016**, 126, 2588-96	15.9	207
121	Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling. *Blood*, **2016**, 128, 1851-1851	2.2	15
120	Tandem CAR T cells targeting HER2 and IL13R□ mitigate tumor antigen escape. *Journal of Clinical Investigation*, **2016**, 126, 3036-52	15.9	355
119	Glycolysis determines dichotomous regulation of T cell subsets in hypoxia. *Journal of Clinical Investigation*, **2016**, 126, 2678-88	15.9	68
118	Chimeric Antigen Receptors for Cancer Immunotherapy. *Methods in Molecular Biology*, **2016**, 1393, 75-86	1.4	2
117	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade. *Molecular Therapy*, **2016**, 24, 1135-1149	11.7	190
116	Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. *Blood*, **2016**, 127, 3350-9	2.2	27
115	Mesenchymal Stromal Cells for Linked Delivery of Oncolytic and Apoptotic Adenoviruses to Non-small-cell Lung Cancers. *Molecular Therapy*, **2015**, 23, 1497-506	11.7	20
114	Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. *Blood*, **2015**, 125, 4103-13	2.2	149
113	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma. *Journal of Clinical Oncology*, **2015**, 33, 1688-96	2.2	607
112	Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. *Nature Medicine*, **2015**, 21, 524-9	50.5	398
111	Oncolytic virus expressing RANTES and IL-15 enhances function of CAR-modified T cells in solid tumors. *OncoImmunology*, **2015**, 4, e988098	7.2	52

110	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs. *Blood*, **2015**, 125, 3905-16	2.2	211
109	Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies. *Current Opinion in Hematology*, **2015**, 22, 489-96	3.3	2
108	Evaluation of Intracellular Signaling Downstream Chimeric Antigen Receptors. *PLoS ONE*, **2015**, 10, e0144787	3.7	67
107	Overcoming the toxicity hurdles of genetically targeted T cells. *Cancer Immunology, Immunotherapy* , **2015**, 64, 123-30	7.4	44
106	K562-Derived Whole-Cell Vaccine Enhances Antitumor Responses of CAR-Redirected Virus-Specific Cytotoxic T Lymphocytes In Vivo. *Clinical Cancer Research*, **2015**, 21, 2952-62	12.9	21
105	Survivin-specific T cell receptor targets tumor but not T cells. *Journal of Clinical Investigation*, **2015**, 125, 157-68	15.9	45
104	Third Generation CD19-CAR T Cells for Relapsed and Refractory Lymphoma and Leukemia Report from the Swedish Phase I/IIa Trial. *Blood*, **2015**, 126, 1534-1534	2.2	9
103	Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas. *Blood*, **2015**, 126, 185-185	2.2	12
102	Cord Blood Derived Natural Killer Cells Engineered with a Chimeric Antigen Receptor Targeting CD19 and Expressing IL-15 Have Long Term Persistence and Exert Potent Anti-Leukemia Activity. *Blood*, **2015**, 126, 3091-3091	2.2	7
101	Safety of Multiple Doses of CAR T Cells. *Blood*, **2015**, 126, 4425-4425	2.2	4
100	Autologous HER2 CMV bispecific CAR T cells for progressive glioblastoma: Results from a phase I clinical trial.. *Journal of Clinical Oncology*, **2015**, 33, 3008-3008	2.2	4
99	T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. *Clinical Cancer Research*, **2014**, 20, 962-71	12.9	58
98	From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. *Seminars in Oncology*, **2014**, 41, 661-6	5.5	22
97	Bortezomib sensitizes non-small cell lung cancer to mesenchymal stromal cell-delivered inducible caspase-9-mediated cytotoxicity. *Cancer Gene Therapy*, **2014**, 21, 472-482	5.4	29
96	Design and development of therapies using chimeric antigen receptor-expressing T cells. *Immunological Reviews*, **2014**, 257, 107-26	11.3	338
95	Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. *Clinical Cancer Research*, **2014**, 20, 131-9	12.9	90
94	Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. *Cancer Research*, **2014**, 74, 5195-205	10.1	194
93	The other face of chimeric antigen receptors. *Molecular Therapy*, **2014**, 22, 899-900	11.7	2

92	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. *Blood*, **2014**, 123, 3750-9	2.2	381
91	Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. *Blood*, **2014**, 123, 3895-905	2.2	131
90	Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. *Blood*, **2014**, 124, 2824-33	2.2	173
89	CD19-CAR trials. *Cancer Journal (Sudbury, Mass)*, **2014**, 20, 112-8	2.2	84
88	Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. *Cytotherapy*, **2014**, 16, 84-9	4.8	32
87	T Cells Expressing CD19-Specific Chimeric Antigen Receptors Are Inhibited By Indoleamine 2,3-Dioxygenase in Tumors. *Blood*, **2014**, 124, 2434-2434	2.2	
86	Chimeric antigen receptors (CARs) from bench-to-bedside. *Immunology Letters*, **2013**, 155, 40-2	4.1	16
85	Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. *Clinical Cancer Research*, **2013**, 19, 106-17	12.9	58
84	T lymphocytes are not immune. *Molecular Therapy*, **2013**, 21, 1114-5	11.7	
83	TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e105	10.7	297
82	Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. *Haematologica*, **2013**, 98, 533-7	6.6	25
81	Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells. *Blood*, **2013**, 122, 142-142	2.2	2
80	Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target [illegible]Light Immunoglobulin Chain. *Blood*, **2013**, 122, 506-506	2.2	6
79	A [illegible]on-fratricidal[illegible]T Cell Receptor That Targets Survivin Expressed By Hematological Malignancies. *Blood*, **2013**, 122, 141-141	2.2	
78	Boosting In Vivo CAR-Redirected Virus-Specific CTLs With Universal-Artificial Antigen Presenting Cells. *Blood*, **2013**, 122, 4204-4204	2.2	
77	Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. *International Journal of Cancer*, **2012** , 130, 1937-47	7.5	71
76	Ex[illegible]vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R[illegible]hull) mice. *Experimental Hematology*, **2012**, 40, 445-56	3.1	76
75	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. *Haematologica*, **2012**, 97, 1622-31	6.6	12

74	Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?. *Molecular Therapy*, **2012**, 20, 246-9	11.7	43
73	IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity. *Journal of Clinical Investigation*, **2012**, 122, 2221-33	15.9	91
72	Improving Immune Reconstitution After Cord Blood Transplantation Using Ex Vivo Expanded Virus-Specific T Cells: A Phase I Clinical Study. *Blood*, **2012**, 120, 224-224	2.2	1
71	Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication. *Blood*, **2012**, 120, 949-949	2.2	3
70	Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia. *Cytotherapy*, **2011**, 13, 1128-39	4.8	13
69	T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. *Blood*, **2011**, 117, 4304-14	2.2	106
68	In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. *Blood*, **2011**, 117, 4736-45	2.2	68
67	Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. *Blood*, **2011**, 118, 6050-6	2.2	813
66	High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells. *Blood*, **2011**, 117, 3353-62	2.2	75
65	Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. *Expert Opinion on Biological Therapy*, **2011**, 11, 855-73	5.4	111
64	PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor. *Molecular Therapy*, **2011**, 19, 2133-43	11.7	95
63	Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. *Cancer Research*, **2011**, 71, 3175-81	10.1	56
62	Inducible apoptosis as a safety switch for adoptive cell therapy. *New England Journal of Medicine*, **2011**, 365, 1673-83	59.2	1031
61	Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. *Journal of Immunology*, **2011**, 187, 5221-32	5.3	47
60	Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination. *Molecular Therapy*, **2011**, 19, 2239-48	11.7	32
59	CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. *Journal of Clinical Investigation*, **2011**, 121, 1822-6	15.9	709
58	Dual Transgenesis of T Cells with a Novel CD44v6-Specific Chimeric Antigen Receptor and a Suicide Gene for Safe and Effective Targeting of Chemoresistance in Hematopoietic Tumors. *Blood*, **2011**, 118, 3125-3125	2.2	
57	T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms. *Molecular Therapy*, **2010**, 18, 2006-17	11.7	59

56	Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. *Cytotherapy*, **2010**, 12, 743-9	4.8	64
55	Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. *Blood*, **2010**, 115, 2695-703	2.2	95
54	Response: To force the expression of CCR4 and/or of CCR5 chemokine receptor in T cells for immunotherapy of Hodgkin lymphoma: that is the question. *Blood*, **2010**, 115, 748-748	2.2	11
53	An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies. *Stem Cells*, **2010**, 28, 1107-15	5.8	68
52	Administration of Tumor-Specific Cytotoxic T Lymphocytes Engineered to Resist TGF-β to Patients with EBV-Associated Lymphomas. *Blood*, **2010**, 116, 560-560	2.2	4
51	Combining Mtor Inhibitors with Rapa-Resistant T Cells: a Two-Pronged Approach to Tumor Elimination. *Blood*, **2010**, 116, 2853-2853	2.2	
50	A New Chimeric Antigen Receptor (CAR) Targeting the CD23 Antigen Expressed by Chronic Lymphocytic Leukemia (B-CLL) Cells. *Blood*, **2010**, 116, 2446-2446	2.2	
49	The Effects of Co-Stimulatory Endodomains on the Fate of T Cells Expressing a Tumor Directed Chimeric Antigen Receptor (CAR) In Human Subjects with B Cell Malignancies. *Blood*, **2010**, 116, 3949-3949	2.2	
48	Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". *Human Gene Therapy*, **2009**, 20, 1229-39	4.8	67
47	Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. *Molecular Therapy*, **2009**, 17, 880-8	11.7	77
46	Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. *Clinical Cancer Research*, **2009**, 15, 5852-60	12.9	100
45	PPM1A and PPM1B act as IKKbeta phosphatases to terminate TNFalpha-induced IKKbeta-NF-kappaB activation. *Cellular Signalling*, **2009**, 21, 95-102	4.9	81
44	Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells. *Stem Cells*, **2009**, 27, 1932-40	5.8	15
43	T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. *Blood*, **2009**, 113, 6392-402	2.2	376
42	Blocking PD-1 in cancer immunotherapy. *Blood*, **2009**, 114, 1457-8	2.2	23
41	Immunotherapy of human cancers using gene modified T lymphocytes. *Current Gene Therapy*, **2009**, 9, 396-408	4.3	25
40	An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies.. *Blood*, **2009**, 114, 1444-1444	2.2	
39	Rapid High Titer Retroviral Production Using a Concentrated Retrovirus Expansion Device (CRED).. *Blood*, **2009**, 114, 2468-2468	2.2	

38	Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. *Nature Medicine*, **2008**, 14, 1264-70	50.5	919
37	Adoptive T-cell immunotherapy of chronic lymphocytic leukaemia. *Best Practice and Research in Clinical Haematology*, **2008**, 21, 375-89	4.2	6
36	Monoculture-Derived T Lymphocytes Providing Multiple Virus Specificity and Anti-Leukemia Activity for Recipients of Hematopietic Stem Cells or Umbilical Cord Blood Transplants. *Blood*, **2008** , 112, 3909-3909	2.2	1
35	A Novel Strategy to Render CTL Resistant to Immunosuppression with Calcineurin Inhibitors. *Blood*, **2008**, 112, 3897-3897	2.2	
34	Generation of Epstein Barr Virus Specific Cytotoxic T Lymphocytes (EBVCTLs) Resistant to the Immunosuppressive Drug Tacrolimus (FK506). *Blood*, **2008**, 112, 3536-3536	2.2	
33	Rapid Generation of Antigen-Specific T Cells for Pre-Clinical and Clinical Applications Using a Novel Mini Cell Bioreactor. *Blood*, **2008**, 112, 208-208	2.2	
32	Selective Loss of a Putative Precursor Population of B-Chronic Lymphocytic Leukemia Cells Following Immunization with hCD40L/IL-2 Expressing Autologous Tumor Cells. *Blood*, **2008**, 112, 3172-3172	2.2	
31	Vaccination Strategies for Patients with B-CLL.. *Blood*, **2008**, 112, 2106-2106	2.2	
30	Cytotoxic T Lymphocytes (CTL) Specific for Adenovirus and CMV Can Be Generated from Umbilical Cord Blood for Adoptive Immunotherapy. *Blood*, **2008**, 112, 3505-3505	2.2	
29	Safely Improving the in Vivo Survival of Tumor Specific Cytotoxic T Lymphocytes by Co-Transfer of IL7 Receptor Alpha Chain and icaspase9. *Blood*, **2008**, 112, 3534-3534	2.2	
28	Polyclonal PRAME-Specific Cytotoxic T Lymphocytes Generated Using Protein-Spanning Pools of Overlapping Pentadecapeptides Target Chronic Myeloid Leukemia. *Blood*, **2008**, 112, 3899-3899	2.2	
27	Engineering CD19-Redirected T Lymphocytes to Enhance Their Safety and Efficacy. *Blood*, **2008**, 112, 824-824	2.2	
26	Regression of experimental medulloblastoma following transfer of HER2-specific T cells. *Cancer Research*, **2007**, 67, 5957-64	10.1	136
25	Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 913-24	4.7	154
24	T-Cells Redirected Against CD70 for the Immunotherapy of Hematological Malignancies.. *Blood*, **2007**, 110, 2757-2757	2.2	1
23	T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. *Blood*, **2006**, 108, 3890-7	2.2	231
22	Generation and Expansion of PRAME-Specific Cytotoxic T-Lymphocytes for Adoptive T-Cell Therapy of Hematological Malignancies.. *Blood*, **2006**, 108, 2205-2205	2.2	
21	Immune Responses Are Induced Against Side-Population B-CLL Stem Cells by Patient Vaccination with hCD40L/IL2 Gene Modified Tumor Cells.. *Blood*, **2006**, 108, 2552-2552	2.2	

20	Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia. *Clinical Cancer Research*, **2005**, 11, 6916-23	12.9	68
19	Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes. *Blood*, **2005**, 105, 2436-42	2.2	44
18	Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. *Blood*, **2005**, 105, 4677-84	2.2	113
17	An inducible caspase 9 safety switch for T-cell therapy. *Blood*, **2005**, 105, 4247-54	2.2	477
16	Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. *American Journal of Transplantation*, **2005**, 5, 566-72	8.7	68
15	A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. *Molecular Therapy*, **2005**, 12, 933-41	11.7	365
14	Three-Module Signaling Endo-Domain Artifical T-Cell Receptor Which Transmits CD28, OX40 and CD3-Signals Enhances IL-2 Release and Proliferative Response in Transduced Primary T-Cells.. *Blood*, **2004**, 104, 1747-1747	2.2	2
13	Fas Down-Modulation in Epstein Barr Virus (EBV)-Specific Cytotoxic T-Lymphocytes (CTLs) Reduces Their Sensitivity to Fas/Fasl-Induced Apoptosis.. *Blood*, **2004**, 104, 2647-2647	2.2	
12	Inducible Caspase 9 as a Safety Switch in Genetically Modified Cytotoxic T Cells.. *Blood*, **2004**, 104, 1743-1743	2.2	
11	Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity. *Blood*, **2003**, 101, 1007-14	2.2	52
10	Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells. *Blood*, **2003**, 102, 3815-21	2.2	130
9	Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells. *Human Gene Therapy*, **2003**, 14, 545-59	4.8	21
8	Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes. *Journal of Virology*, **2003**, 77, 10872-80	6.6	101
7	Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. *British Journal of Haematology*, **2002**, 116, 202-10	4.5	34
6	Lymphomas occurring late after solid-organ transplantation: influence of treatment on the clinical outcome. *Transplantation*, **2002**, 74, 1095-102	1.8	119
5	Transgenic expression of CD40 ligand produces an in vivo antitumor immune response against both CD40(+) and CD40(-) plasmacytoma cells. *Blood*, **2002**, 100, 200-7	2.2	20
4	Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes. *Human Gene Therapy*, **2001**, 12, 659-70	4.8	54
3	Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. *Transplantation*, **2000**, 69, 827-33	1.8	126

2	Effect of the protein tyrosine kinase inhibitor genistein on normal and leukaemic haemopoietic progenitor cells. *British Journal of Haematology*, **1996**, 93, 551-7	4.5	17
1	Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors. *Advanced Functional Materials*,2009489	15.6	13